FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

BODALCHEM Consensus Forecast

No. of reports in last year
2
No. of analysts
1
Average Consensus Forecast
68
Consensus Potential
2.60%

BODALCHEM Price Target Potential

BrokerageTargetPotential
Kotak Securities65-1.69%

BODALCHEM Targets in FrontPage Forums

0 Users have submitted 0 trade ideas of Rs. 0 for BODALCHEM
0% Bullish
0% Bearish
See buy or sell ideas on FrontPage Forums >>

BODALCHEM Ratings

Long term BODALCHEM rating by FrontPage users
1/5 (2 Ratings)

2 BODALCHEM share price target reports by brokerages below. See what is analyst's view on BODALCHEM share price forecast, rating, estimates, valuation and prediction behind the target. You may use these research report forecasts for long-term to medium term for your investment or trades in 2020.
  1. Home
  2. BODALCHEM Forum
  3. BODALCHEM Price Target

BODALCHEM Share Price Target

BODALCHEM Share Price Target - Broker Reports - 2019

15-Nov-19
Price @ Call: 66.84
Target: 65
SELL
Given the future road map in terms of revenue visibility and margin expansion plans in place, by undertaking an aggressive capex plan, we believe that long term story still remains intact. However, in the near term given the slowdown in terms of subdued demand across the end user segment, which is impacting an average realization shall weigh on the performance. In addition, the weak performance from Trion Chemicals (facing technical and safety related issues) would also weigh on overall performance. Though we believe the current valuation of 10.0x/7.5 x FY20E/FY21E earnings, factors in negative news and stock is trading at a fair valuation given the industry dynamics, but we do not foresee improvement in margin (which we had seen in past due to higher realization and return ratios). Hence, we discontinue the coverage on the stock with a SELL rating and revised target price of Rs65 (earlier Rs 71), valuing it at 7x FY21E earnings
... Read more
16-Aug-19
Price @ Call: 73.04
Target: 71
SELL
The stock is down ~35% since our last report dated 22nd May, 2019 (rating SELL) and at current valuation of 8.1x/7.6X FY20E/FY21E earnings, trading at fair valuation given the industry dynamics (weakness in demand and lower realization as capacity in China ramp-up) and re-rating will take some time. Hence, we continue to retain our SELL rating, with a revised target price of Rs.71 (earlier Rs109), valuing it at 7x FY21E earnings.
... Read more
23-May-19
Price @ Call: 113
Target: 105
REDUCE
Volume growth in SPS, Trion and Thionol Chloride will remain the key growth driver for next two years until the new capacity comes on stream. However, China turbulence can impact realisation growth thereby putting pressure on operating margins. Moreover, any negative surprise on FCF generation due to lower OPM and extension in working capital can impact the payback cycle of upcoming capex. We value the company at EV/EBITDA of 5x and arrive a target price of Rs 105. We have a REDUCE rating on the stock.
... Read more
22-May-19
Price @ Call: 116
Target: 109
SELL
Factoring 4QFY19 performance, we have revised our FY20E earnings to Rs12.7 (earlier Rs13) and introducing FY21E with earnings estimate of Rs13.6. The stock is up ~18% since our last report dated 7th Feb, 2019 (rating BUY) and at CMP, we believe that at current valuation of 9.0x/8.4X FY20E/FY21E earnings, the stock is trading at fair valuation and re-rating will take some more time. Hence, we recommend SELL (earlier BUY) on the stock (valuing at 8x FY21E EPS), with a revised target price of Rs109 (earlier Rs117), as we roll forward our valuation multiple to FY21E.
... Read more
7-Feb-19
Price @ Call: 98.55
Target: 117
BUY

BODALCHEM Share Price Target - Broker Reports - 2018

26-Oct-18
Price @ Call: 118.16
Target: 130
ACCUMULATE
28-Mar-18
Price @ Call: 120.07
Target: 150
BUY
12-Feb-18
Price @ Call: 152.23
Target: 164
ACCUMULATE

BODALCHEM Share Price Target - Broker Reports - 2017

24-Oct-17
Price @ Call: 171.55
Target: 249
BUY
29-Aug-17
Price @ Call: 168.69
Target: 200
BUY
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • BODALCHEM Share Price Target Today- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 368.53
    Upside Target 267.22
    Upside Target 165.38
    Pivot64.07
    Downside Target 162.23
    Downside Target 260.92
    Downside Target 359.08
  • BODALCHEM Share Price Target weekly- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 375.37
    Upside Target 272.68
    Upside Target 168.12
    Pivot65.43
    Downside Target 160.87
    Downside Target 258.18
    Downside Target 353.62
  • BODALCHEM Share Price Target monthly- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 387.83
    Upside Target 275.97
    Upside Target 167.83
    Pivot55.97
    Downside Target 147.83
    Downside Target 235.97
    Downside Target 327.83
  • BODALCHEM Share Price Target today- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 367.22
    Upside Target 266.01
    Upside Target 165.27
    Pivot64.07
    Downside Target 162.86
    Downside Target 262.12
    Downside Target 360.92
  • BODALCHEM Share Price Target weekly- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 372.68
    Upside Target 269.91
    Upside Target 168.2
    Pivot65.43
    Downside Target 162.66
    Downside Target 260.95
    Downside Target 358.18
  • BODALCHEM Share Price Target monthly- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 375.97
    Upside Target 268.33
    Upside Target 163.61
    Pivot55.97
    Downside Target 148.33
    Downside Target 243.61
    Downside Target 335.97
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.
PrivacyTerms
FrontPage © 2020